Extreme concentrations of endogenous sex hormones, ischemic heart disease, and death in women

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 2, 2015, Pages 471-477

  Benn, Marianne ^a,b   Voss, Sidsel Skou ^a   Holmegard, Haya N ^a   Jensen, Gorm B ^a   Tybjærg Hansen, Anne ^a,b   Nordestgaard, Børge G ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

death; epidemiology; estrogens; general social development and population; gonadal steroid hormones; myocardial infarction; myocardial ischemia; testosterone

Indexed keywords

ESTRADIOL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TESTOSTERONE; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DEATH; DIASTOLIC BLOOD PRESSURE; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; ISCHEMIC HEART DISEASE; NEOPLASM; POSTMENOPAUSE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TESTOSTERONE BLOOD LEVEL; BLOOD; CAUSE OF DEATH; DENMARK; DOWN REGULATION; EPIDEMIOLOGY; MIDDLE AGED; MORTALITY; MYOCARDIAL ISCHEMIA; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME; UPREGULATION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CAUSE OF DEATH; DENMARK; DOWN-REGULATION; ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TESTOSTERONE; TIME FACTORS; UP-REGULATION; YOUNG ADULT;

EID: 84922062748     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.304821     Document Type: Article

References (30)

1. Villablanca AC, Jayachandran M, Banka C. Atherosclerosis and sex hormones: current concepts. Clin Sci (Lond). 2010;119:493-513. doi:10.1042/ CS20100248.
2. Barrett-Connor E, Goodman-Gruen D. Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women. BMJ. 1995;311:1193-1196.
3. Laughlin GA, Goodell V, Barrett-Connor E. Extremes of endogenous testosterone are associated with increased risk of incident coronary events in older women. J Clin Endocrinol Metab. 2010;95:740-747. doi:10.1210/ jc.2009-1693.
4. Sievers C, Klotsche J, Pieper L, Schneider HJ, März W, Wittchen HU, Stalla GK, Mantzoros C. Low testosterone levels predict all-cause mortality and cardiovascular events in women: a prospective cohort study in German primary care patients. Eur J Endocrinol. 2010;163:699-708. doi:10.1530/EJE-10-0307.
5. Scarabin-Carré V, Canonico M, Brailly-Tabard S, Trabado S, Ducimetière P, Giroud M, Ryan J, Helmer C, Plu-Bureau G, Guiochon-Mantel A, Scarabin PY. High level of plasma estradiol as a new predictor of ischemic arterial disease in older postmenopausal women: the threecity cohort study. J Am Heart Assoc. 2012;1:e001388. doi:10.1161/ JAHA.112.001388.
6. Burger HG, Dudley EC, Hopper JL, Groome N, Guthrie JR, Green A, Dennerstein L. Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women. J Clin Endocrinol Metab. 1999;84:4025-4030. doi:10.1210/jcem.84.11.6158.
7. Bancroft J, Cawood EH. Androgens and the menopause; a study of 40-60-year-old women. Clin Endocrinol (Oxf). 1996;45:577-587.
8. Rozenberg S, Bosson D, Peretz A, Caufriez A, Robyn C. Serum levels of gonadotrophins and steroid hormones in the post-menopause and later life. Maturitas. 1988;10:215-224.
9. Burger HG, Dudley EC, Cui J, Dennerstein L, Hopper JL. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metab. 2000;85:2832-2838. doi:10.1210/ jcem.85.8.6740.
10. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab. 2005;90:3847-3853. doi:10.1210/jc.2005-0212.
11. Haring R, Hannemann A, John U, Radke D, Nauck M, Wallaschofski H, Owen L, Adaway J, Keevil BG, Brabant G. Age-specific reference ranges for serum testosterone and androstenedione concentrations in women measured by liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab. 2012;97:408-415. doi:10.1210/jc.2011-2134.
12. Derby CA, Crawford SL, Pasternak RC, Sowers M, Sternfeld B, Matthews KA. Lipid changes during the menopause transition in relation to age and weight: the Study of Women's Health Across the Nation. Am J Epidemiol. 2009;169:1352-1361. doi:10.1093/aje/kwp043.
13. Gulhan I, Bozkaya G, Uyar I, Oztekin D, Pamuk BO, Dogan E. Serum lipid levels in women with premature ovarian failure. Menopause. 2012;19:1231-1234. doi:10.1097/gme.0b013e318254102b.
14. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev. 2003;24:313-340. doi:10.1210/er.2003-0005.
15. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801-1811. doi:10.1056/ NEJM199906103402306.
16. Vassalle C, Simoncini T, Chedraui P, Pérez-López FR. Why sex matters: the biological mechanisms of cardiovascular disease. Gynecol Endocrinol. 2012;28:746-751. doi:10.3109/09513590.2011.652720.
17. Miller VM. Sex-based differences in vascular function. Womens Health (Lond Engl). 2010;6:737-752. doi:10.2217/whe.10.53.
18. Pedram A, Razandi M, Sainson RC, Kim JK, Hughes CC, Levin ER. A conserved mechanism for steroid receptor translocation to the plasma membrane. J Biol Chem. 2007;282:22278-22288. doi:10.1074/jbc.M611877200.
19. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science. 2005;307:1625-1630. doi:10.1126/science.1106943.
20. Han G, Li F, Yu X, White RE. GPER: a novel target for non-genomic estrogen action in the cardiovascular system. Pharmacol Res. 2013;71:53-60. doi:10.1016/j.phrs.2013.02.008.
21. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-1037.
22. Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SA, Brzyski R, Chlebowski RT, Gass M, LaCroix A, Manson JE, Prentice RL, Rossouw J, Stefanick ML; WHI Investigators. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA. 2008;299:1036-1045. doi:10.1001/jama.299.9.1036.
23. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
24. Shifren JL, Davis SR, Moreau M, Waldbaum A, Bouchard C, DeRogatis L, Derzko C, Bearnson P, Kakos N, O'Neill S, Levine S, Wekselman K, Buch A, Rodenberg C, Kroll R. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause. 2006;13:770-779. doi:10.1097/01.gme.0000243567.32828.99.
25. Davis SR, Moreau M, Kroll R, Bouchard C, Panay N, Gass M, Braunstein GD, Hirschberg AL, Rodenberg C, Pack S, Koch H, Moufarege A, Studd J; APHRODITE Study Team. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med. 2008;359:2005-2017. doi:10.1056/NEJMoa0707302.
26. Panay N, Al-Azzawi F, Bouchard C, Davis SR, Eden J, Lodhi I, Rees M, Rodenberg CA, Rymer J, Schwenkhagen A, Sturdee DW. Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric. 2010;13:121-131. doi:10.3109/13697131003675922.
27. White WB, Grady D, Giudice LC, Berry SM, Zborowski J, Snabes MC. A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorder. Am Heart J. 2012;163:27-32. doi:10.1016/j.ahj.2011.09.021.
28. Lidegaard O, Løkkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012;366:2257-2266. doi:10.1056/ NEJMoa1111840.
29. Smith NL, Blondon M, Wiggins KL, Harrington LB, van Hylckama Vlieg A, Floyd JS, Hwang M, Bis JC, McKnight B, Rice KM, Lumley T, Rosendaal FR, Heckbert SR, Psaty BM. Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens. JAMA Intern Med. 2014;174:25-31. doi:10.1001/jamainternmed.2013.11074.
30. Vermeulen A, Verdonck G. Representativeness of a single point plasma testosterone level for the long term hormonal milieu in men. J Clin Endocrinol Metab. 1992;74:939-942. doi:10.1210/jcem.74.4.1548361.